By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Operon Biotechnologies must pay Qiagen $2.1 million as a result of an arbitration panel ruling, Qiagen disclosed in a regulatory filing.

In its quarterly earning document filed with the US Securities and Exchange Commission earlier this month, Qiagen said that the arbitration panel ruled in its favor in a supply agreement dispute between the two companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.